NYLIM
RCKT icon

New York Life Investment Management’s Rocket Pharmaceuticals RCKT Stock Holding History

New York Life Investment Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-35,766
Closed -$700K – 1351
2022
Q4 		$700K Buy
35,766
+4,032
+13% +$74.3K 0.01% 680
2022
Q3 		$506K Buy
31,734
+2,331
+8% +$36.4K 0.01% 732
2022
Q2 		$405K Buy
+29,403
New +$351K ﹤0.01% 948

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

New York Life Investment Management's RCKT Position: Q1 2023 in Review

New York Life Investment Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2023, closing a stake of 35,766 shares — an estimated $700K sold.

New York Life Investment Management first reported a position in RCKT in Q2 2022 and held it in 3 quarters. The position peaked at $700K in Q4 2022. 163 funds tracked by Wall St. Rank hold RCKT as of Q1 2023.

  • New York Life Investment Management reported no remaining Rocket Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 35,766 Rocket Pharmaceuticals shares in Q1 2023, an estimated $700K.
  • New York Life Investment Management first reported a position in Rocket Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Rocket Pharmaceuticals position peaked at $700K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.